高级搜索

雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效

岳 顺, 张大红, 周磊磊

岳 顺, 张大红, 周磊磊. 雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效[J]. 肿瘤防治研究, 2014, 41(02): 160-162. DOI: 10.3971/j.issn.1000-8578.2014.02.016
引用本文: 岳 顺, 张大红, 周磊磊. 雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效[J]. 肿瘤防治研究, 2014, 41(02): 160-162. DOI: 10.3971/j.issn.1000-8578.2014.02.016
shu
YUE Shun, ZHANG Dahong, ZHOU Leilei. Clinical Efficacy of Raltitrexed Combined with Docetaxel for Advanced Gastric Cacinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 160-162. DOI: 10.3971/j.issn.1000-8578.2014.02.016
Citation: YUE Shun, ZHANG Dahong, ZHOU Leilei. Clinical Efficacy of Raltitrexed Combined with Docetaxel for Advanced Gastric Cacinoma[J]. Cancer Research on Prevention and Treatment, 2014, 41(02): 160-162. DOI: 10.3971/j.issn.1000-8578.2014.02.016
shu

雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效

  • 223300江苏淮安，南京医科大学附属淮安第一医院肿瘤内科

详细信息
    作者简介:

    岳顺（1964-），男，本科，主任医师，主要从事肿瘤内科工作

  • 中图分类号: R735.2

Clinical Efficacy of Raltitrexed Combined with Docetaxel for Advanced Gastric Cacinoma

  • Department of Oncology,First Hospital of Huaian,Affiliated to Nanjing Medical University,Huaian 223300, China

HTML全文

    摘要
  • 摘要: 目的 探讨雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效及安全性。方法 90例晚期胃癌患者随机分为A、B组，A组45例采用雷替曲塞联合多西他赛化疗方案；B组45例采用多西他赛化疗方案。治疗2周期后，比较两组患者的疗效及不良反应。结果 患者接受治疗后均可评价疗效。A组总有效率(53.33%)显著高于B组(31.11%)，差异具有统计学意义；两组主要不良反应均为骨髓抑制、恶心呕吐、脱发、关节酸痛、外周神经炎、口腔黏膜炎等，且A组骨髓抑制、关节酸痛、转氨酶升高和贫血的发生率高于B组，但无显著差异；两组未见因不良反应延缓化疗的患者，且无化疗相关性死亡。结论 雷替曲塞联合多西他赛方案治疗晚期胃癌疗效优于多西他赛，且不良反应较轻，值得临床推广使用。

     

    Abstract: Objective To explore clinical efficacy and safety of raltitrexed combined with docetaxel in the treatment of advanced gastric carcinoma. Methods Ninety patients with advanced gastric carcinoma were randomly divided into groups A and B. Group A (45 cases) was given the chemotherapy of raltitrexed combined with docetaxel, while group B (45 cases) given docetaxel alone chemotherapy. The therapeutic effects, toxic and side effects of 2 groups were compared after 2 cycles of treatments. Results The therapeutic effects of all patients after chemotherapy were evaluated. The total effective rate (53.33%) in group A was significantly higher than that of group B (31.11%), and the difference showed statistical significance. Toxic and side effects of 2 groups mainly included myelosuppression, nausea and vomiting, alopecia, joint pain, peripheral neuritis and oral mucositis, and the incidences of myelosuppression, joint pain, increased transaminase and anemia in group A were higher than those in group B, but there were no signifi cant difference. There were no patients whose chemotherapy was delayed due to toxic reactions, and no chemotherapy-related death. Conclusion The therapeutic effects of raltitrexed combined with docetaxel in the treatment of advanced gastric carcinoma are better than that of docetaxel alone, and its toxic and side effects are slight, so it is worthy of being popularized and applied in clinic.

     

    • HTML全文
    • 参考文献(10)
  • [1] Long JL, Yi QH, Ren ZX, et al. Clinical observation of docetaxel combined with cisplatine and fl uorouracil in the fi rst-line therapy of 35 patients with advanced gastric cancer[J]. Chongqing Yi Xue,2010, 39(18): 2490-4.[龙建林, 易全会, 任章霞, 等. 多西他 赛联合顺铂、氟尿嘧啶一线治疗35例晚期胃癌临床观察[J].重 庆医学,2010,39(18):2490-4.]
    [2] Li RZ, Liu HF. Present status of chemotherapy on advanced gastric cancer[J]. Zhong Liu Xue Za Zhi, 2006, 12(6): 504-7.[李瑞中, 刘 汉锋. 进展期胃癌的化学药物治疗现状[J]. 肿瘤学杂志, 2006, 12 (6): 504-7.]
    [3] Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefi t with gemcitabine as fi rst-line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997, 15(6): 2403-13.
    [4] Sun Y, Shi YK.Clinical oncology manual[M]. Beijing:People's Medical Publishing House,2007:476.[孙燕, 石远凯. 临床肿瘤内 科手册[M]. 北京:人民卫生出版社,2007:476.]
    [5] Louvet C, André T, Tigaud JM, et al. Phase II study of oxaliplatin, fluorouracil,and folinic acid in locally advanced or metastatic gastric cancer patients[J]. J Clin Oncol, 2002, 20(23): 4543-8.
    [6] Gravalos C, Salut A, García-Girón C, et al. A randomized phase II study to compare oxaliplatin plus 5-fl uorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as fi rstline chemotherapy for advanced colorectal cancer[J]. Clin Transl Oncol, 2012,14(8):606-12.
    [7] Shen J, Wang H, Wei J, et al. Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer[J]. Int J Cancer, 2012, 13 1(6): E938-45.
    [8] Chen JL, Song WF, Chen DH. Meta analysis on clinical effects of raltitrexed for advanced colorectal cancer[J]. Zhongguo Xin Yao Yu Lin Chuang Za Zhi, 2010, 16(11): 53-6.[陈建林, 宋卫峰, 陈 栋晖. 雷替曲塞治疗晚期结直肠癌临床疗效的Meta分析[J]. 中 国新药与临床杂志, 2010, 16(11): 53-6.]
    [9] Li J. Strategies of diagnosis and treatment on medical oncology[M]. Shanghai: Shanghai Science and Technology Press, 2007: 70-8.[李 进. 肿瘤内科诊治策略[M]. 上海: 上海科学技术出版社, 2007: 70 -8.]
    [10] Huo D, Zhang XL, Ma YF, et al. Clinical research of raltitrexed combined with docetaxel for advanced gastric cancer[J]. Zhongguo Xian Dai Yi Yao Za Zhi, 2011, 13(10): 27-9.[霍丹, 张小丽, 马玉 芳, 等. 雷替曲塞联合多西他赛治疗晚期胃癌的临床研究[J]. 中 国现代医药杂志, 2011, 13(10): 27-9.]
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  1378
  • HTML全文浏览量:  324
  • PDF下载量:  702
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-11-12
  • 修回日期:  2013-03-28
  • 刊出日期:  2014-02-24

目录

摘要
HTML全文
    参考文献(10)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11647727 今日访问：15076

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭